What Is the Optimal Digoxin Level? Challenging Case of Fetal Atrial Flutter Treatment in a Monochorionic Diamniotic Twin

Background: Atrial flutter is an infrequent yet potentially fatal arrhythmia. Digoxin is the preferred first-line treatment for fetal atrial flutter due to its efficacy and favorable safety profile. The optimal digoxin serum target level for neonatal atrial flutter management remains uncertain, with the standard target level ranging from 1.0 to 2.0 ng/mL due to potential toxicity concerns above this threshold. Case Presentation: We present a case of atrial flutter in a fetus within a monochorionic diamniotic (MCDA) twin pregnancy that was successfully managed using a higher-than-standard target level of digoxin. A 34-year-old nulliparous woman was referred to our institution at 31 + 3 weeks of gestation due to fetal distress in an MCDA twin pregnancy. Fetal echocardiography revealed a ventricular rate of 214 bpm in twin A, while twin B exhibited no abnormal findings. Conclusions: Our case highlights a distinct correlation between the serum digoxin level and its impact on atrial flutter. A higher target serum level of digoxin may be necessary to achieve sinus conversion due to the unique maternal and fetal circulatory characteristics in MCDA pregnancies.

[1]  Amalia Făgărășan,et al.  Fetal Tachyarrhythmia Management from Digoxin to Amiodarone—A Review , 2022, Journal of clinical medicine.

[2]  G. Antiñolo,et al.  Maternal effects induced by oral digoxin during treatment of fetal tachyarrhythmia: Case series and literature review. , 2020, European journal of obstetrics, gynecology, and reproductive biology.

[3]  E. Gratacós,et al.  Uncomplicated Monochorionic Twins: Two Normal Hearts Sharing One Placenta , 2020, Journal of clinical medicine.

[4]  M. Respondek-Liberska,et al.  Successful treatment of neonatal atrial flutter by synchronized cardioversion: case report and literature review , 2020, BMC Pediatrics.

[5]  G. Zaharie,et al.  Fetal cardiovascular alterations in twin-to-twin transfusion syndrome , 2020, Medicine and pharmacy reports.

[6]  W. Shimizu,et al.  Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial. , 2019, Journal of the American College of Cardiology.

[7]  M. Esposito,et al.  Maternal monitoring and safety considerations during antiarrhythmic treatment for fetal supraventricular tachycardia , 2018, Obstetric medicine.

[8]  N. Bravo-Valenzuela,et al.  Fetal cardiac arrhythmias: Current evidence , 2018, Annals of pediatric cardiology.

[9]  J. Marek,et al.  Flecainide versus digoxin for fetal supraventricular tachycardia: Comparison of two drug treatment protocols. , 2016, Heart rhythm.

[10]  R. Wakai,et al.  Fetal Atrial Flutter: Electrophysiology and Associations With Rhythms Involving an Accessory Pathway , 2016, Journal of the American Heart Association.

[11]  E. Jaeggi,et al.  Fetal and Neonatal Arrhythmias. , 2016, Clinics in perinatology.

[12]  J. Rychik,et al.  Diagnosis and Treatment of Fetal Cardiac Disease: A Scientific Statement From the American Heart Association , 2014, Circulation.

[13]  B. McCrindle,et al.  Comparison of Transplacental Treatment of Fetal Supraventricular Tachyarrhythmias With Digoxin, Flecainide, and Sotalol: Results of a Nonrandomized Multicenter Study , 2011, Circulation.

[14]  Hanmin Liu,et al.  Transplacental digoxin therapy for fetal tachyarrhythmia with multiple evaluation systems , 2011, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[15]  J. Simpson,et al.  Review of diagnosis, treatment, and outcome of fetal atrial flutter compared with supraventricular tachycardia , 2003, Heart.

[16]  D. Campbell,et al.  The importance of plasma volume expansion and nutrition in twin pregnancy. , 1985, Acta geneticae medicae et gemellologiae.